 Naresh Mandava
Concepts (360)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macular Degeneration | 21 | 2023 | 152 | 5.050 |
Why?
| | Geographic Atrophy | 7 | 2023 | 49 | 2.250 |
Why?
| | Visual Acuity | 18 | 2023 | 274 | 2.140 |
Why?
| | Retinal Detachment | 6 | 2023 | 53 | 2.130 |
Why?
| | Diabetic Retinopathy | 11 | 2023 | 149 | 1.970 |
Why?
| | Wet Macular Degeneration | 5 | 2023 | 32 | 1.800 |
Why?
| | Angiogenesis Inhibitors | 17 | 2023 | 214 | 1.790 |
Why?
| | Retinal Drusen | 3 | 2021 | 25 | 1.640 |
Why?
| | Registries | 4 | 2020 | 1767 | 1.280 |
Why?
| | Vitreous Body | 15 | 2022 | 101 | 1.160 |
Why?
| | Vitrectomy | 12 | 2020 | 57 | 1.130 |
Why?
| | Macula Lutea | 2 | 2023 | 15 | 1.060 |
Why?
| | Retina | 10 | 2021 | 263 | 0.930 |
Why?
| | Antibodies, Monoclonal | 9 | 2011 | 1262 | 0.860 |
Why?
| | Retinal Diseases | 4 | 2023 | 76 | 0.860 |
Why?
| | Vascular Endothelial Growth Factor A | 12 | 2023 | 498 | 0.860 |
Why?
| | Retinal Neovascularization | 2 | 2019 | 20 | 0.780 |
Why?
| | Choroidal Neovascularization | 6 | 2019 | 44 | 0.770 |
Why?
| | Fluorescein Angiography | 15 | 2023 | 102 | 0.750 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.740 |
Why?
| | Retinal Perforations | 4 | 2015 | 12 | 0.720 |
Why?
| | Quarantine | 1 | 2020 | 24 | 0.710 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 116 | 0.630 |
Why?
| | Retinitis Pigmentosa | 3 | 2021 | 16 | 0.610 |
Why?
| | Tomography, Optical Coherence | 10 | 2022 | 130 | 0.610 |
Why?
| | Intraocular Pressure | 6 | 2012 | 276 | 0.550 |
Why?
| | Automobile Driving | 1 | 2018 | 128 | 0.550 |
Why?
| | Aged, 80 and over | 15 | 2021 | 6344 | 0.550 |
Why?
| | Epiretinal Membrane | 3 | 2010 | 6 | 0.550 |
Why?
| | Aged | 27 | 2023 | 19061 | 0.540 |
Why?
| | Scleral Buckling | 3 | 2019 | 18 | 0.510 |
Why?
| | Antibodies, Monoclonal, Humanized | 11 | 2015 | 663 | 0.490 |
Why?
| | Humans | 76 | 2023 | 114616 | 0.480 |
Why?
| | Self Report | 1 | 2018 | 696 | 0.480 |
Why?
| | Optic Neuropathy, Ischemic | 3 | 2013 | 30 | 0.460 |
Why?
| | Female | 46 | 2023 | 59461 | 0.450 |
Why?
| | Recombinant Fusion Proteins | 4 | 2013 | 616 | 0.450 |
Why?
| | Surveys and Questionnaires | 4 | 2022 | 4620 | 0.440 |
Why?
| | Research Design | 1 | 2019 | 928 | 0.430 |
Why?
| | Choroid | 5 | 2021 | 47 | 0.430 |
Why?
| | Follow-Up Studies | 13 | 2021 | 4411 | 0.430 |
Why?
| | Retinopathy of Prematurity | 3 | 2020 | 111 | 0.430 |
Why?
| | Bevacizumab | 11 | 2015 | 115 | 0.420 |
Why?
| | Male | 44 | 2023 | 55549 | 0.420 |
Why?
| | Pandemics | 1 | 2020 | 1317 | 0.400 |
Why?
| | Retinal Necrosis Syndrome, Acute | 2 | 2013 | 9 | 0.400 |
Why?
| | Retinal Vein Occlusion | 2 | 2015 | 13 | 0.390 |
Why?
| | Photography | 4 | 2015 | 88 | 0.390 |
Why?
| | Endophthalmitis | 3 | 2017 | 25 | 0.380 |
Why?
| | Uveal Diseases | 2 | 2013 | 5 | 0.380 |
Why?
| | Middle Aged | 28 | 2021 | 26719 | 0.370 |
Why?
| | Cataract | 2 | 2020 | 185 | 0.370 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2015 | 36 | 0.350 |
Why?
| | Colorado | 7 | 2023 | 4099 | 0.350 |
Why?
| | Complement Factor B | 2 | 2022 | 100 | 0.340 |
Why?
| | Visual Fields | 3 | 2022 | 77 | 0.340 |
Why?
| | Glycogen Storage Disease Type IIb | 2 | 2007 | 22 | 0.340 |
Why?
| | Prospective Studies | 7 | 2023 | 6214 | 0.330 |
Why?
| | Vision, Low | 4 | 2022 | 14 | 0.330 |
Why?
| | Pigment Epithelium of Eye | 2 | 2006 | 34 | 0.320 |
Why?
| | Complement Activation | 3 | 2022 | 340 | 0.320 |
Why?
| | Injections | 6 | 2010 | 159 | 0.320 |
Why?
| | Retrospective Studies | 22 | 2023 | 12542 | 0.320 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2014 | 1183 | 0.320 |
Why?
| | Ophthalmology | 2 | 2013 | 77 | 0.310 |
Why?
| | Ocular Hypertension | 1 | 2009 | 61 | 0.310 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2007 | 49 | 0.290 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2007 | 10 | 0.290 |
Why?
| | Macular Edema | 2 | 2015 | 34 | 0.290 |
Why?
| | Optic Nerve Injuries | 1 | 2007 | 4 | 0.290 |
Why?
| | Phacoemulsification | 3 | 2020 | 107 | 0.290 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2007 | 19 | 0.290 |
Why?
| | Vision Disorders | 2 | 2022 | 130 | 0.280 |
Why?
| | Quantum Dots | 2 | 2021 | 35 | 0.280 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 11 | 0.280 |
Why?
| | Papilledema | 1 | 2007 | 40 | 0.280 |
Why?
| | Fovea Centralis | 2 | 2010 | 8 | 0.280 |
Why?
| | Glucocorticoids | 2 | 2013 | 532 | 0.280 |
Why?
| | Puerperal Disorders | 1 | 2007 | 30 | 0.270 |
Why?
| | RNA, Catalytic | 1 | 2007 | 182 | 0.270 |
Why?
| | Herpesvirus 1, Human | 1 | 2007 | 76 | 0.270 |
Why?
| | Triamcinolone Acetonide | 1 | 2006 | 27 | 0.270 |
Why?
| | Ocular Hypotension | 1 | 2006 | 10 | 0.260 |
Why?
| | Ciliary Body | 1 | 2006 | 33 | 0.260 |
Why?
| | Myopia | 1 | 2006 | 36 | 0.260 |
Why?
| | Telangiectasis | 1 | 2005 | 6 | 0.260 |
Why?
| | Granuloma | 1 | 2006 | 83 | 0.250 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 45 | 0.250 |
Why?
| | DNA, Viral | 1 | 2007 | 350 | 0.250 |
Why?
| | Retinal Vessels | 1 | 2005 | 50 | 0.250 |
Why?
| | Retinal Ganglion Cells | 4 | 2022 | 92 | 0.240 |
Why?
| | Diabetes Mellitus | 2 | 2023 | 900 | 0.240 |
Why?
| | Laser Therapy | 2 | 2021 | 100 | 0.240 |
Why?
| | Fluorocarbons | 1 | 2005 | 94 | 0.230 |
Why?
| | Vision Tests | 1 | 2023 | 15 | 0.230 |
Why?
| | Temporal Arteries | 2 | 2015 | 47 | 0.220 |
Why?
| | Disease Models, Animal | 4 | 2012 | 3531 | 0.220 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 3 | 2013 | 103 | 0.210 |
Why?
| | Hemianopsia | 1 | 2022 | 9 | 0.210 |
Why?
| | Risk Factors | 9 | 2023 | 8628 | 0.210 |
Why?
| | Optic Disk | 3 | 2010 | 38 | 0.200 |
Why?
| | Ophthalmoscopy | 2 | 2015 | 30 | 0.190 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.190 |
Why?
| | Cross-Sectional Studies | 4 | 2020 | 4405 | 0.190 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 10 | 0.190 |
Why?
| | Capsule Opacification | 1 | 2021 | 20 | 0.190 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.190 |
Why?
| | Complement System Proteins | 2 | 2022 | 282 | 0.190 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 50 | 0.180 |
Why?
| | Ranibizumab | 5 | 2013 | 18 | 0.180 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.180 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 92 | 0.180 |
Why?
| | Nerve Fibers | 2 | 2010 | 87 | 0.170 |
Why?
| | Herpesvirus 3, Human | 2 | 2015 | 378 | 0.170 |
Why?
| | Intravitreal Injections | 6 | 2020 | 45 | 0.170 |
Why?
| | Electrodes, Implanted | 2 | 2018 | 91 | 0.170 |
Why?
| | Odds Ratio | 2 | 2019 | 953 | 0.170 |
Why?
| | Protective Factors | 1 | 2019 | 87 | 0.170 |
Why?
| | Ischemia | 2 | 2017 | 362 | 0.170 |
Why?
| | C-Reactive Protein | 1 | 2021 | 362 | 0.160 |
Why?
| | Biomarkers | 4 | 2023 | 3405 | 0.160 |
Why?
| | Intraoperative Complications | 1 | 2020 | 122 | 0.160 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 33 | 0.160 |
Why?
| | Complement C3a | 1 | 2019 | 33 | 0.160 |
Why?
| | Cohort Studies | 5 | 2020 | 4894 | 0.160 |
Why?
| | Postoperative Complications | 3 | 2021 | 2127 | 0.160 |
Why?
| | Quality of Life | 4 | 2022 | 2353 | 0.160 |
Why?
| | Visual Prosthesis | 1 | 2018 | 1 | 0.160 |
Why?
| | Metformin | 1 | 2021 | 276 | 0.150 |
Why?
| | Reproducibility of Results | 2 | 2023 | 2762 | 0.150 |
Why?
| | Orbit | 2 | 2010 | 59 | 0.150 |
Why?
| | Anterior Eye Segment | 1 | 2017 | 9 | 0.140 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2017 | 34 | 0.140 |
Why?
| | Time Factors | 4 | 2021 | 6112 | 0.140 |
Why?
| | Strabismus | 1 | 2017 | 26 | 0.140 |
Why?
| | Labor, Induced | 1 | 2017 | 32 | 0.140 |
Why?
| | Laser Coagulation | 3 | 2012 | 54 | 0.140 |
Why?
| | Labor, Obstetric | 1 | 2017 | 52 | 0.140 |
Why?
| | Giant Cell Arteritis | 2 | 2015 | 48 | 0.140 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2017 | 57 | 0.140 |
Why?
| | Phenotype | 3 | 2022 | 2796 | 0.130 |
Why?
| | Retinal Degeneration | 2 | 2015 | 30 | 0.130 |
Why?
| | Immunosuppressive Agents | 2 | 2013 | 646 | 0.130 |
Why?
| | Case-Control Studies | 2 | 2020 | 3001 | 0.130 |
Why?
| | Incidence | 2 | 2020 | 2311 | 0.130 |
Why?
| | Recovery of Function | 1 | 2019 | 574 | 0.130 |
Why?
| | Blindness | 3 | 2013 | 37 | 0.130 |
Why?
| | Treatment Outcome | 7 | 2021 | 9084 | 0.130 |
Why?
| | Gyrate Atrophy | 1 | 2015 | 2 | 0.130 |
Why?
| | Vitreoretinal Surgery | 1 | 2015 | 3 | 0.120 |
Why?
| | Eye Infections, Bacterial | 1 | 2015 | 26 | 0.120 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1430 | 0.120 |
Why?
| | Vitreous Detachment | 1 | 2015 | 5 | 0.120 |
Why?
| | Needles | 1 | 2015 | 49 | 0.120 |
Why?
| | Inflammation | 3 | 2023 | 2477 | 0.120 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 20 | 0.120 |
Why?
| | Antiviral Agents | 2 | 2013 | 645 | 0.120 |
Why?
| | Biopsy, Needle | 1 | 2015 | 182 | 0.120 |
Why?
| | Wounds, Gunshot | 2 | 2010 | 190 | 0.120 |
Why?
| | Proteomics | 1 | 2020 | 835 | 0.120 |
Why?
| | Logistic Models | 1 | 2019 | 1840 | 0.120 |
Why?
| | Oculomotor Muscles | 1 | 2014 | 40 | 0.120 |
Why?
| | Adult | 15 | 2020 | 30528 | 0.120 |
Why?
| | Proteins | 1 | 2020 | 908 | 0.120 |
Why?
| | Rats, Inbred BN | 3 | 2011 | 52 | 0.120 |
Why?
| | Fundus Oculi | 3 | 2014 | 40 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 2 | 2021 | 447 | 0.110 |
Why?
| | Fibrin | 1 | 2014 | 65 | 0.110 |
Why?
| | Premature Birth | 1 | 2017 | 276 | 0.110 |
Why?
| | Uvea | 1 | 2013 | 1 | 0.110 |
Why?
| | Exchange Transfusion, Whole Blood | 1 | 2013 | 15 | 0.110 |
Why?
| | Uveomeningoencephalitic Syndrome | 1 | 2013 | 6 | 0.110 |
Why?
| | Drug Packaging | 2 | 2011 | 42 | 0.110 |
Why?
| | Retinal Artery Occlusion | 1 | 2013 | 8 | 0.110 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2013 | 11 | 0.110 |
Why?
| | Tendons | 1 | 2014 | 120 | 0.110 |
Why?
| | Cytomegalovirus Retinitis | 1 | 2013 | 17 | 0.110 |
Why?
| | Isoxazoles | 1 | 2013 | 51 | 0.110 |
Why?
| | Lymphoproliferative Disorders | 1 | 2013 | 46 | 0.110 |
Why?
| | Retinal Pigment Epithelium | 1 | 2013 | 58 | 0.100 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2014 | 122 | 0.100 |
Why?
| | Silicon | 1 | 2012 | 13 | 0.100 |
Why?
| | Viremia | 1 | 2013 | 122 | 0.100 |
Why?
| | Lens Subluxation | 1 | 2012 | 3 | 0.100 |
Why?
| | Trabecular Meshwork | 1 | 2013 | 77 | 0.100 |
Why?
| | Placenta | 1 | 2018 | 625 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 275 | 0.100 |
Why?
| | Exanthema | 1 | 2013 | 74 | 0.100 |
Why?
| | Uveitis, Posterior | 1 | 2012 | 12 | 0.100 |
Why?
| | Diagnosis, Differential | 4 | 2013 | 1342 | 0.100 |
Why?
| | Particulate Matter | 2 | 2011 | 185 | 0.100 |
Why?
| | Fluocinolone Acetonide | 1 | 2012 | 16 | 0.100 |
Why?
| | Electric Stimulation Therapy | 1 | 2012 | 56 | 0.100 |
Why?
| | Microsurgery | 1 | 2012 | 59 | 0.100 |
Why?
| | Gestational Age | 3 | 2020 | 759 | 0.100 |
Why?
| | Global Health | 1 | 2014 | 287 | 0.100 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2011 | 61 | 0.090 |
Why?
| | Fluorescein-5-isothiocyanate | 2 | 2009 | 37 | 0.090 |
Why?
| | Electroretinography | 2 | 2012 | 40 | 0.090 |
Why?
| | Silicone Oils | 1 | 2011 | 26 | 0.090 |
Why?
| | Drug Storage | 1 | 2011 | 58 | 0.090 |
Why?
| | Glaucoma | 2 | 2010 | 202 | 0.090 |
Why?
| | Dextrans | 2 | 2009 | 73 | 0.090 |
Why?
| | Health Care Costs | 1 | 2014 | 381 | 0.090 |
Why?
| | Dissection | 1 | 2011 | 51 | 0.090 |
Why?
| | Anemia, Sickle Cell | 1 | 2013 | 215 | 0.090 |
Why?
| | Antioxidants | 1 | 2014 | 530 | 0.090 |
Why?
| | Infliximab | 2 | 2007 | 94 | 0.090 |
Why?
| | United States | 3 | 2020 | 12176 | 0.090 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 373 | 0.090 |
Why?
| | Protein Multimerization | 1 | 2011 | 157 | 0.090 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 2 | 2007 | 26 | 0.090 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2009 | 59 | 0.080 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2009 | 45 | 0.080 |
Why?
| | Bacteria | 1 | 2015 | 725 | 0.080 |
Why?
| | Tonometry, Ocular | 1 | 2009 | 83 | 0.080 |
Why?
| | Rats | 4 | 2012 | 4958 | 0.080 |
Why?
| | Herpes Zoster | 1 | 2013 | 331 | 0.080 |
Why?
| | Scotoma | 1 | 2008 | 4 | 0.080 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 254 | 0.070 |
Why?
| | Retinal Artery | 1 | 2007 | 15 | 0.070 |
Why?
| | Vitreous Hemorrhage | 1 | 2007 | 6 | 0.070 |
Why?
| | Cerebral Angiography | 1 | 2007 | 109 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2009 | 1842 | 0.070 |
Why?
| | Acyclovir | 1 | 2007 | 100 | 0.070 |
Why?
| | Ultrasonography | 2 | 2007 | 633 | 0.070 |
Why?
| | Frameshift Mutation | 1 | 2006 | 27 | 0.070 |
Why?
| | Secondary Prevention | 1 | 2007 | 222 | 0.070 |
Why?
| | Internationality | 2 | 2018 | 143 | 0.070 |
Why?
| | Indocyanine Green | 1 | 2005 | 12 | 0.070 |
Why?
| | Conjunctival Neoplasms | 1 | 2005 | 7 | 0.070 |
Why?
| | beta-Thalassemia | 1 | 2006 | 23 | 0.060 |
Why?
| | Eye Injuries, Penetrating | 1 | 2005 | 17 | 0.060 |
Why?
| | Coloring Agents | 1 | 2005 | 72 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2009 | 429 | 0.060 |
Why?
| | Eye Foreign Bodies | 1 | 2005 | 23 | 0.060 |
Why?
| | Pregnancy | 3 | 2018 | 5517 | 0.060 |
Why?
| | Eye Injuries | 1 | 2006 | 44 | 0.060 |
Why?
| | Uveitis | 1 | 2006 | 115 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2007 | 1139 | 0.060 |
Why?
| | Staining and Labeling | 1 | 2005 | 134 | 0.060 |
Why?
| | Metals | 1 | 2005 | 106 | 0.060 |
Why?
| | Mydriatics | 1 | 2004 | 3 | 0.060 |
Why?
| | Pupil | 1 | 2004 | 13 | 0.060 |
Why?
| | Animals | 6 | 2014 | 31692 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 993 | 0.060 |
Why?
| | Young Adult | 6 | 2019 | 10455 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2008 | 1691 | 0.060 |
Why?
| | Sclera | 2 | 2014 | 35 | 0.060 |
Why?
| | Hospitals, County | 1 | 2023 | 10 | 0.060 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2007 | 348 | 0.060 |
Why?
| | Observer Variation | 1 | 2004 | 295 | 0.050 |
Why?
| | Double-Blind Method | 1 | 2007 | 1660 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 797 | 0.050 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 382 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 206 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 31 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 89 | 0.050 |
Why?
| | Retreatment | 2 | 2012 | 67 | 0.050 |
Why?
| | Fibrinogen | 1 | 2022 | 154 | 0.050 |
Why?
| | Lenses, Intraocular | 1 | 2021 | 42 | 0.050 |
Why?
| | Drug Compounding | 2 | 2011 | 89 | 0.050 |
Why?
| | Equipment Design | 2 | 2014 | 508 | 0.040 |
Why?
| | Electric Stimulation | 1 | 2021 | 250 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2007 | 2552 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1578 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 220 | 0.040 |
Why?
| | Cell Survival | 2 | 2013 | 1020 | 0.040 |
Why?
| | Melanoma | 1 | 2005 | 619 | 0.040 |
Why?
| | Infant | 3 | 2020 | 7954 | 0.040 |
Why?
| | Postoperative Period | 1 | 2019 | 289 | 0.040 |
Why?
| | Prevalence | 2 | 2015 | 2249 | 0.040 |
Why?
| | Primary Health Care | 1 | 2008 | 1512 | 0.040 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 18 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2020 | 5040 | 0.040 |
Why?
| | Combined Modality Therapy | 2 | 2013 | 1121 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2022 | 632 | 0.040 |
Why?
| | Birth Weight | 1 | 2020 | 440 | 0.040 |
Why?
| | Iris Diseases | 1 | 2017 | 5 | 0.040 |
Why?
| | Choroid Diseases | 1 | 2017 | 9 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2022 | 640 | 0.040 |
Why?
| | Mental Health | 1 | 2022 | 562 | 0.040 |
Why?
| | Prosthesis Implantation | 1 | 2018 | 138 | 0.030 |
Why?
| | Parity | 1 | 2017 | 98 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2017 | 125 | 0.030 |
Why?
| | Adolescent | 3 | 2012 | 17830 | 0.030 |
Why?
| | Risk | 1 | 2018 | 812 | 0.030 |
Why?
| | Microbiological Techniques | 1 | 2015 | 29 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2015 | 111 | 0.030 |
Why?
| | Myopia, Degenerative | 1 | 2015 | 3 | 0.030 |
Why?
| | Endotamponade | 1 | 2015 | 4 | 0.030 |
Why?
| | Disease Progression | 2 | 2015 | 2380 | 0.030 |
Why?
| | Tissue Adhesions | 1 | 2015 | 26 | 0.030 |
Why?
| | Tenon Capsule | 1 | 2014 | 3 | 0.030 |
Why?
| | Cerebral Arterial Diseases | 1 | 2015 | 42 | 0.030 |
Why?
| | Atrophy | 1 | 2015 | 152 | 0.030 |
Why?
| | Biometry | 1 | 2014 | 62 | 0.030 |
Why?
| | Conjunctiva | 1 | 2014 | 51 | 0.030 |
Why?
| | Lens Implantation, Intraocular | 1 | 2015 | 57 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1736 | 0.030 |
Why?
| | Fetus | 1 | 2018 | 699 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1008 | 0.030 |
Why?
| | Child, Preschool | 1 | 2007 | 9106 | 0.030 |
Why?
| | Infant, Premature | 1 | 2017 | 476 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2014 | 217 | 0.030 |
Why?
| | Safety-net Providers | 1 | 2014 | 95 | 0.030 |
Why?
| | Adaptation, Ocular | 1 | 2012 | 4 | 0.030 |
Why?
| | Dark Adaptation | 1 | 2012 | 13 | 0.030 |
Why?
| | Rats, Mutant Strains | 1 | 2012 | 25 | 0.030 |
Why?
| | Sclerostomy | 1 | 2012 | 4 | 0.030 |
Why?
| | Mothers | 1 | 2018 | 651 | 0.030 |
Why?
| | Cytomegalovirus | 1 | 2013 | 144 | 0.030 |
Why?
| | Drug Implants | 1 | 2012 | 70 | 0.020 |
Why?
| | Cell Count | 1 | 2012 | 303 | 0.020 |
Why?
| | Gold | 1 | 2012 | 106 | 0.020 |
Why?
| | Swine | 1 | 2014 | 699 | 0.020 |
Why?
| | Bruch Membrane | 1 | 2011 | 6 | 0.020 |
Why?
| | Polyglycolic Acid | 1 | 2011 | 43 | 0.020 |
Why?
| | Administration, Oral | 1 | 2013 | 728 | 0.020 |
Why?
| | Miniaturization | 1 | 2011 | 23 | 0.020 |
Why?
| | Drug Stability | 1 | 2011 | 151 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2011 | 159 | 0.020 |
Why?
| | Immunoglobulin Light Chains | 1 | 2010 | 35 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1448 | 0.020 |
Why?
| | Chromatography, Gel | 1 | 2010 | 122 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2010 | 72 | 0.020 |
Why?
| | Fluorescein | 1 | 2010 | 25 | 0.020 |
Why?
| | Molecular Weight | 1 | 2010 | 331 | 0.020 |
Why?
| | Particle Size | 1 | 2011 | 317 | 0.020 |
Why?
| | Aptamers, Nucleotide | 1 | 2010 | 73 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 318 | 0.020 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2010 | 70 | 0.020 |
Why?
| | Lactic Acid | 1 | 2011 | 275 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 742 | 0.020 |
Why?
| | Poverty Areas | 1 | 2008 | 32 | 0.020 |
Why?
| | Fibroblasts | 1 | 2013 | 837 | 0.020 |
Why?
| | Optic Nerve Diseases | 1 | 2008 | 31 | 0.020 |
Why?
| | Community Health Centers | 1 | 2008 | 54 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2010 | 301 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 811 | 0.020 |
Why?
| | Models, Biological | 1 | 2015 | 1620 | 0.020 |
Why?
| | Pilot Projects | 1 | 2012 | 1372 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 2013 | 541 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2010 | 510 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2011 | 561 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1477 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 682 | 0.020 |
Why?
| | Pedigree | 1 | 2007 | 460 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 3881 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 371 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 497 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2537 | 0.010 |
Why?
| | Mass Screening | 1 | 2008 | 1004 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2010 | 2279 | 0.010 |
Why?
| | Risk Assessment | 1 | 2008 | 2967 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2012 | 2094 | 0.010 |
Why?
| | Aging | 1 | 2008 | 1618 | 0.010 |
Why?
| | Mutation | 1 | 2007 | 3344 | 0.010 |
Why?
| | Child | 1 | 2012 | 18402 | 0.010 |
Why?
|
|
Mandava's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|